Kymera Therapeutics [KYMR] vs Madrigal [MDGL] Detailed Stock Comparison
Kymera Therapeutics
NASDAQ
Loading...
Madrigal
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Kymera Therapeutics wins in 7 metrics, Madrigal wins in 10 metrics, with 0 ties. Madrigal appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Kymera Therapeutics | Madrigal | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -19.43 | -20.23 | Madrigal |
| Price-to-Book Ratio | 4.21 | 14.14 | Kymera Therapeutics |
| Debt-to-Equity Ratio | 8.82 | 17.81 | Kymera Therapeutics |
| PEG Ratio | -0.30 | 0.28 | Kymera Therapeutics |
| EV/EBITDA | -11.67 | -29.84 | Madrigal |
| Profit Margin (TTM) | 0.00% | -54.68% | Kymera Therapeutics |
| Operating Margin (TTM) | -736.82% | -22.18% | Madrigal |
| Return on Equity | -33.26% | -36.30% | Kymera Therapeutics |
| Return on Assets (TTM) | -19.92% | -18.31% | Madrigal |
| Free Cash Flow (TTM) | $-207.34M | $-462.03M | Kymera Therapeutics |
| 1-Year Return | 27.83% | 106.54% | Madrigal |
| Price-to-Sales Ratio (TTM) | 92.59 | 19.15 | Madrigal |
| Enterprise Value | $3.56B | $9.20B | Madrigal |
| EV/Revenue Ratio | 79.62 | 17.85 | Madrigal |
| Gross Profit Margin (TTM) | N/A | 95.74% | N/A |
| Revenue per Share (TTM) | $1 | $23 | Madrigal |
| Earnings per Share (Diluted) | $-3.49 | $-12.63 | Kymera Therapeutics |
| Beta (Stock Volatility) | 2.27 | -1.03 | Madrigal |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Kymera Therapeutics vs Madrigal Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Kymera Therapeutics | -0.60% | -1.62% | 33.03% | 31.36% | 161.47% | 40.74% |
| Madrigal | -0.16% | -0.18% | -2.53% | 52.96% | 42.44% | 40.96% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Kymera Therapeutics | 27.83% | 161.59% | 49.95% | 73.03% | 73.03% | 73.03% |
| Madrigal | 106.54% | 583.74% | 253.20% | 538.25% | 229.10% | 28.30% |
News Based Sentiment: Kymera Therapeutics vs Madrigal
Kymera Therapeutics
News based Sentiment: POSITIVE
Kymera experienced a highly positive month marked by strategic partnerships with Sanofi and Gilead, significant progress across its clinical pipeline, and a wave of analyst upgrades. These developments signal growing confidence in the company's potential and have driven substantial stock performance, making it a noteworthy event for investors.
Madrigal
News based Sentiment: POSITIVE
Madrigal Pharmaceuticals reported exceptional revenue growth in Q2 2025 and received numerous positive analyst updates, indicating strong market confidence. While some insider and institutional selling occurred, the overall narrative for the month is positive, driven by the company's financial performance and future growth prospects.
Performance & Financial Health Analysis: Kymera Therapeutics vs Madrigal
| Metric | KYMR | MDGL |
|---|---|---|
| Market Information | ||
| Market Cap | $4.26B | $9.87B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 879,850 | 284,740 |
| 90 Day Avg. Volume | 836,827 | 331,680 |
| Last Close | $57.55 | $442.31 |
| 52 Week Range | $19.44 - $59.00 | $200.63 - $463.63 |
| % from 52W High | -2.46% | -4.60% |
| All-Time High | $91.92 (Dec 28, 2020) | $463.62 (Oct 01, 2025) |
| % from All-Time High | -37.39% | -4.60% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.55% | 13.54% |
| Quarterly Earnings Growth | -0.55% | 13.54% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | -0.55% |
| Operating Margin (TTM) | -7.37% | -0.22% |
| Return on Equity (TTM) | -0.33% | -0.36% |
| Debt to Equity (MRQ) | 8.82 | 17.81 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $13.77 | $31.32 |
| Cash per Share (MRQ) | $9.31 | $35.76 |
| Operating Cash Flow (TTM) | $-251,008,000 | $-307,412,992 |
| Levered Free Cash Flow (TTM) | $-153,841,376 | $-219,782,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Kymera Therapeutics vs Madrigal
| Metric | KYMR | MDGL |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -19.43 | -20.23 |
| Forward P/E | -18.62 | -31.73 |
| PEG Ratio | -0.30 | 0.28 |
| Price to Sales (TTM) | 92.59 | 19.15 |
| Price to Book (MRQ) | 4.21 | 14.14 |
| Market Capitalization | ||
| Market Capitalization | $4.26B | $9.87B |
| Enterprise Value | $3.56B | $9.20B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 79.62 | 17.85 |
| Enterprise to EBITDA | -11.67 | -29.84 |
| Risk & Other Metrics | ||
| Beta | 2.27 | -1.03 |
| Book Value per Share (MRQ) | $13.77 | $31.32 |
Financial Statements Comparison: Kymera Therapeutics vs Madrigal
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | KYMR | MDGL |
|---|---|---|
| Revenue/Sales | $11.48M | $137.25M |
| Cost of Goods Sold | N/A | $4.51M |
| Gross Profit | N/A | $132.74M |
| Research & Development | $78.39M | $44.17M |
| Operating Income (EBIT) | $-84.56M | $-79.31M |
| EBITDA | $-74.42M | $-69.56M |
| Pre-Tax Income | $-76.61M | $-73.24M |
| Income Tax | N/A | N/A |
| Net Income (Profit) | $-76.61M | $-73.24M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | KYMR | MDGL |
|---|---|---|
| Cash & Equivalents | $89.97M | $183.65M |
| Total Current Assets | $500.95M | $987.98M |
| Total Current Liabilities | $58.99M | $167.24M |
| Long-Term Debt | $73.09M | $118.76M |
| Total Shareholders Equity | $786.23M | $710.64M |
| Retained Earnings | $-820.19M | $-1.88B |
| Property, Plant & Equipment | $18.88M | $4.01M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | KYMR | MDGL |
|---|---|---|
| Operating Cash Flow | $-67.71M | $-81.76M |
| Capital Expenditures | $-467,000 | $0 |
| Free Cash Flow | $-79.62M | $-88.89M |
| Debt Repayment | $-277,000 | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | KYMR | MDGL |
|---|---|---|
| Shares Short | 7.46M | 4.14M |
| Short Ratio | 11.82 | 10.95 |
| Short % of Float | 0.13% | 0.22% |
| Average Daily Volume (10 Day) | 879,850 | 284,740 |
| Average Daily Volume (90 Day) | 836,827 | 331,680 |
| Shares Outstanding | 64.89M | 22.00M |
| Float Shares | 46.96M | 10.98M |
| % Held by Insiders | 0.03% | 0.08% |
| % Held by Institutions | 1.12% | 1.08% |
Dividend Analysis & Yield Comparison: Kymera Therapeutics vs Madrigal
| Metric | KYMR | MDGL |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |